secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001104659-25-119095
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports positive Phase 2 data for oral GLP-1 aleniglipron; plans Phase 3 by mid-2026
--------------------------------------------------------------------------------

- Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at 120 mg in Phase 2b ACCESS study; up to 15.3% (35.5 lbs) at 240 mg in exploratory ACCESS II.
- No AE-related discontinuations when starting at 2.5 mg in OLE and body composition studies, improving tolerability vs 5 mg start.
- No cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation across all aleniglipron studies.
- Plans to request Type B End-of-Phase 2 meeting with FDA in H1 2026; Phase 3 program initiation expected by mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/0001104659-25-119095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/tm2532078d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-119095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer